Also trades as: XTLB.TA (TLV) · $vol 0M
XTLB NASDAQ
XTL Biopharmaceuticals Ltd.
1W: -1.8%
1M: -18.8%
3M: -31.2%
YTD: +260.3%
1Y: +87.8%
3Y: +109.7%
5Y: -47.5%
$2.16
+0.03 (+1.41%)
Weekly Expected Move ±9.6%
$2
$2
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$2M
-128.9% ▼
Capital Expenditures
$54K
+0.0% ▲
5Y CAGR: +93.3%
Free Cash Flow
-$2M
-136.5% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$1M
-48.6% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$3M | $435K | -$1M | -$2M | -$1M |
| Depreciation & Amort. | $1K | $1K | $1K | $0 | $199K |
| Stock-Based Comp. | $51K | $37K | $14K | $3K | $264K |
| Change in Working Capital | $45K | -$54K | -$19K | $64K | $189K |
| Other Non-Cash Items | $2M | -$1M | -$36K | $1M | -$1M |
| Operating Cash Flow | -$850K | -$1M | -$901K | -$707K | -$2M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1K | $0 | $0 | $0 | -$54K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | -$410K |
| Investment Purchases | $0 | $0 | $0 | $0 | -$14K |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $33K | $8K | $36K | $41K | -$366K |
| Investing Cash Flow | $32K | $8K | $36K | $41K | -$844K |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | -$13K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $0 | $385K | $0 | $0 | $1M |
| Net Change in Cash | -$824K | -$662K | -$875K | -$693K | -$1M |
| Cash End of Period | $4M | $3M | $2M | $1M | $371K |
| Free Cash Flow | -$851K | -$1M | -$901K | -$707K | -$2M |